Advances and challenges in therapeutic targeting of NRF2
AT Dinkova-Kostova, IM Copple - Trends in pharmacological sciences, 2023 - cell.com
Activation of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is
emerging as an attractive therapeutic approach to counteract oxidative stress, inflammation …
emerging as an attractive therapeutic approach to counteract oxidative stress, inflammation …
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
The transcription factor NF-E2 p45-related factor 2 (NRF2; encoded by NFE2L2) and its
principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 …
principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 …
Therapeutic advances in multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …
causes significant disability and healthcare burden. The treatment of MS has evolved over …
Treatment of multiple sclerosis—success from bench to bedside
M Tintore, A Vidal-Jordana… - Nature Reviews …, 2019 - nature.com
The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
NRF2 as a regulator of cell metabolism and inflammation in cancer
Nuclear factor erythroid 2‐related factor 2 (NRF2) is a master transcriptional regulator of
genes whose products defend our cells for toxic and oxidative insults. Although NRF2 …
genes whose products defend our cells for toxic and oxidative insults. Although NRF2 …
High-efficacy therapies for treatment-naïve individuals with relapsing–remitting multiple sclerosis
L Freeman, EE Longbrake, PK Coyle, B Hendin… - CNS drugs, 2022 - Springer
There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …
action currently approved by the US Food and Drug Administration for the treatment of …
Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
G Giovannoni, P Soelberg Sorensen… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: In the 2-year CLARITY study, cladribine tablets significantly improved clinical
and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing …
and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing …
A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future
Background Multiple sclerosis (MS) is a chronic and autoimmune disease of the central
nervous system (CNS), mainly characterized by inflammatory demyelination, which …
nervous system (CNS), mainly characterized by inflammatory demyelination, which …
[PDF][PDF] Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
JJ Cerqueira, DAS Compston, R Geraldes… - Journal of Neurology …, 2018 - jnnp.bmj.com
The management of multiple sclerosis (MS) has been a neurology success story for the past
25 years. Advances in understanding of the disease mechanisms and the dynamic nature of …
25 years. Advances in understanding of the disease mechanisms and the dynamic nature of …
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
Background The mechanism of action of oral cladribine, recently licensed for relapsing
multiple sclerosis, is unknown. Objective To determine whether cladribine depletes memory …
multiple sclerosis, is unknown. Objective To determine whether cladribine depletes memory …